News Articles and Montana BioScience Alliance Newsletters
New technology developed by researchers at Montana State University, featured this month on the cover of the journal Science Advances, could have powerful impacts on the way scientists study viruses, make vaccines or splice genes.
For a fifth straight year, Montana State University recorded an all-time high for research expenditures — the funding put toward scientific discovery and other scholastic and creative pursuits. MSU is the largest research enterprise in the state, and its total expenditures exceed the research expenditures of all other institutions in the state combined.
Central Montana Medical Center has broken ground on a $15.6 million cancer center that will bring comprehensive cancer care services to central Montana. That means residents living in central and northern Montana won’t have to travel as long for cancer treatment.
A vaccine to prevent overdosing on fentanyl and one for heroin are in the works at the University of Montana and partner institutions. Human trials are expected to start in early 2024 for both vaccines, according to UM.
Only three years after its creation, the University of Montana and University of Montana Foundation today announced a significant investment to benefit the L.S. Skaggs Institute for Health Innovation. Known as SIHI, the institute will use this investment to expand its influence as a statewide hub for health education, research and outreach — with a goal of improving access to emerging health innovations for all Montanans.
Drug makers have been racing at a breakneck pace to develop respiratory syncytial virus (RSV) vaccines this year. On May 3, the U.S. Food and Drug Administration (FDA) announced it has approved Arexvy, the first-ever RSV vaccine for individuals 60 and over.
Information on Small Business Funding Webinar, National Small Business Week, America’s SEED Fund Week — and more
SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year. The next deadline is April 5. Omnibus Solicitations. Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These FOAs do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations. Specific Funding […]
FDA advisers endorsed the safety and efficacy of GSK’s respiratory syncytial virus (RSV) vaccine in older adults, setting up a final mad dash with Pfizer as both companies eye the regulatory finish line with their promising new vaccines.
Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.
View the Summer 2023 Newsletter now!
View the Spring 2023 Newsletter now!